Dzifa Dey

Dzifa Dey

Auto-generated profile, based on publicly available information

Dzifa Dey

Department of Medicine and Therapeutics, University of Ghana Medical School, Legon, Accra, Ghana

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2017 in Lupus
Verified
Journal Article
Closed access
DDD Dzifa
D Dzifa
VBVincent Boima
Vincent Boima
EYE Yorke
E Yorke
AYA Yawson
A Yawson
VGV Ganu
V Ganu
CMC Mate-Kole
C Mate-Kole
Although it was previously believed that systemic lupus erythematosus was uncommon among Africans, it has become increasingly apparent that the incidence is higher, and socioeconomic challenges such as physician shortages, poor medical facility access, and poor health literacy may worsen prognosis. This retrospective study examines characteristics and outcomes of hospitalized systemic lupus erythematosus patients over a two-year period and serves as a baseline for comparison for future studies to examine the outcomes with the provision of more dedicated care. There were 51 patient admissions over a two-year period, with a mean duration from start of illness to admission of approximately two years. Duration of admission ranged from one to 140 days with a mean period of 26.12 days (SD ± 26.6). There were 22 deaths (43.1% of admissions), which were mainly due to infections and renal complications. Factors associated with risk of death in regression analysis were: infections, fever, disease flare, musculoskeletal involvement, amenorrhea, depression, a clinical finding of hepatomegaly, and chest infection. Understanding the effect and outcome of systemic lupus erythematosus across different countries can elucidate the role of genetic, environmental, and other causative factors in the progression of the disease.

21 September 2022 in The Lancet Rheumatology
Verified
Journal Article
Closed access
DDDzifa Dey
Dzifa Dey
FPFarhanah Paruk
Farhanah Paruk
GMGirish M Mody
Girish M Mody
AKAsgar A Kalla
Asgar A Kalla
AAAdewale O. Adebajo
Adewale O. Adebajo
IHIhsane Hmamouchi
Ihsane Hmamouchi

10 March 2019 in Ghana Medical Journal
Verified
Journal Article
Open access
PDF file
DDDzifa Dey
Dzifa Dey
EOEmmanuel Ofori
Emmanuel Ofori
KHKojo A Hutton-Mensah
Kojo A Hutton-Mensah
MAMartin Luther King Akutek
Martin Luther King Akutek
RORafiq Okine
Rafiq Okine
HKHarriet Kwarko
Harriet Kwarko
Clinical characteristics of males with systemic lupus erythematosus (SLE) in an inception cohort of patients in Ghana


13 April 2021 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
VBVincent Boima
Vincent Boima
MAM. B. Amissah-Arthur
M. B. Amissah-Arthur
EYE. Yorke
E. Yorke
DDD. Dey
D. Dey
DFDelali Fiagbe
Delali Fiagbe
CMC. C. Mate-Kole
C. C. Mate-Kole
Background: The burden of chronic kidney disease in Africa is three to four times higher compared to high-income countries and the cost of treatment is beyond the reach of most affected persons. The best treatment for end stage renal disease is kidney transplantation which is not available in most African countries. As kidney transplantation surgery is emerging in Ghana, this study assessed factors which could influence the willingness of patients with chronic kidney disease to accept it as a mode of treatment.Methods: This cross-sectional survey was carried out among patients with chronic kidney disease in Korle-Bu Teaching Hospital. A consecutive sampling method was used to recruit consenting patients. A structured questionnaire and standardized research instruments were used to obtain information on demographic, socio-economic characteristics, knowledge about transplantation, perception of transplantation, religiosity and spirituality. Logistic regression model was used to assess the determinants of willingness to accept a kidney transplant.Results: 342 CKD patients participated in the study of which 56.7% (n = 194) were male. The mean age of the participants was 50.24 ± 17.08 years. The proportion of participants who were willing to accept a kidney transplant was 67.3% (95%CI: 62.0–72.2%). The factors which influenced participants’ willingness to accept this treatment included; willingness to attend a class on kidney transplantation (p < 0.016), willingness to donate a kidney if they had the chance (p < 0.005), perception that a living person could donate a kidney (p < 0.001) and perceived improvement in quality of life after transplantation (p < 0.005). The barriers for accepting kidney transplantation were anticipated complications of transplant surgery and financial constraints.Conclusion: More than two-thirds of CKD patients were willing to accept a kidney transplant and this is influenced by multiple factors. Government health agencies must consider full or partial coverage of kidney transplantation through the existing national health insurance scheme. Further, efficient educational programmes are required to improve both patients’ and physicians’ knowledge on the importance of kidney transplantation in the management of end stage renal disease in Ghana.

23 June 2023 in Rheumatology International
Verified
Journal Article
Open access
PDF file
BDBohdana Doskaliuk
Bohdana Doskaliuk
NRNaveen Ravichandran
Naveen Ravichandran
PSParikshit Sen
Parikshit Sen
JDJessica Day
Jessica Day
MJMrudula Joshi
Mrudula Joshi
LGLatika Gupta
Latika Gupta
Limited evidence on long-term COVID-19 vaccine safety in patients with idiopathic inflammatory myopathies (IIMs) continues to contribute to vaccine hesitancy. We studied delayed-onset vaccine adverse events (AEs) in patients with IIMs, other systemic autoimmune and inflammatory disorders (SAIDs), and healthy controls (HCs), using data from the second COVID-19 Vaccination in Autoimmune Diseases (COVAD) study. A validated self-reporting e-survey was circulated by the COVAD study group (157 collaborators, 106 countries) from Feb–June 2022. We collected data on demographics, comorbidities, IIM/SAID details, COVID-19 history, and vaccination details. Delayed-onset (> 7 day) AEs were analyzed using regression models. A total of 15165 respondents undertook the survey, of whom 8759 responses from vaccinated individuals [median age 46 (35–58) years, 74.4% females, 45.4% Caucasians] were analyzed. Of these, 1390 (15.9%) had IIMs, 50.6% other SAIDs, and 33.5% HCs. Among IIMs, 16.3% and 10.2% patients reported minor and major AEs, respectively, and 0.72% (n = 10) required hospitalization. Notably patients with IIMs experienced fewer minor AEs than other SAIDs, though rashes were expectedly more than HCs [OR 4.0; 95% CI 2.2–7.0, p < 0.001]. IIM patients with active disease, overlap myositis, autoimmune comorbidities, and ChadOx1 nCOV-19 (Oxford/AstraZeneca) recipients reported AEs more often, while those with inclusion body myositis, and BNT162b2 (Pfizer) recipients reported fewer AEs. Vaccination is reassuringly safe in individuals with IIMs, with AEs, hospitalizations comparable to SAIDs, and largely limited to those with autoimmune multimorbidity and active disease. These observations may inform guidelines to identify high-risk patients warranting close monitoring in the post-vaccination period.